1. Home
  2. SLNG vs SKYE Comparison

SLNG vs SKYE Comparison

Compare SLNG & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLNG
  • SKYE
  • Stock Information
  • Founded
  • SLNG 2013
  • SKYE 2012
  • Country
  • SLNG United States
  • SKYE United States
  • Employees
  • SLNG N/A
  • SKYE N/A
  • Industry
  • SLNG Oil/Gas Transmission
  • SKYE Biotechnology: Pharmaceutical Preparations
  • Sector
  • SLNG Utilities
  • SKYE Health Care
  • Exchange
  • SLNG Nasdaq
  • SKYE Nasdaq
  • Market Cap
  • SLNG 85.4M
  • SKYE 80.7M
  • IPO Year
  • SLNG N/A
  • SKYE N/A
  • Fundamental
  • Price
  • SLNG $7.79
  • SKYE $2.85
  • Analyst Decision
  • SLNG Strong Buy
  • SKYE Buy
  • Analyst Count
  • SLNG 1
  • SKYE 6
  • Target Price
  • SLNG $12.00
  • SKYE $18.67
  • AVG Volume (30 Days)
  • SLNG 28.9K
  • SKYE 202.8K
  • Earning Date
  • SLNG 03-05-2025
  • SKYE 02-18-2025
  • Dividend Yield
  • SLNG N/A
  • SKYE N/A
  • EPS Growth
  • SLNG N/A
  • SKYE N/A
  • EPS
  • SLNG 0.21
  • SKYE N/A
  • Revenue
  • SLNG $74,044,000.00
  • SKYE N/A
  • Revenue This Year
  • SLNG N/A
  • SKYE N/A
  • Revenue Next Year
  • SLNG N/A
  • SKYE N/A
  • P/E Ratio
  • SLNG $36.44
  • SKYE N/A
  • Revenue Growth
  • SLNG N/A
  • SKYE N/A
  • 52 Week Low
  • SLNG $3.77
  • SKYE $2.31
  • 52 Week High
  • SLNG $8.28
  • SKYE $19.41
  • Technical
  • Relative Strength Index (RSI)
  • SLNG 64.14
  • SKYE 46.60
  • Support Level
  • SLNG $5.95
  • SKYE $2.60
  • Resistance Level
  • SLNG $8.28
  • SKYE $3.54
  • Average True Range (ATR)
  • SLNG 0.73
  • SKYE 0.50
  • MACD
  • SLNG 0.03
  • SKYE 0.02
  • Stochastic Oscillator
  • SLNG 81.44
  • SKYE 18.60

About SLNG Stabilis Solutions Inc.

Stabilis Solutions Inc is an energy transition company that provides turnkey clean energy production, storage, transportation, and fueling solutions using liquefied natural gas (LNG) to multiple end markets. The company provides LNG solutions to customers in diverse end markets, including aerospace, agriculture, energy, industrials, marine bunkering, mining, pipeline, remote power, and utility markets. It generates revenue by selling and delivering LNG to its customers, renting cryogenic equipment, and providing engineering and field support services. It has a geographical presence in the United States and Mexico.

About SKYE Skye Bioscience Inc. Common Stock

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: